

Applicants: William C. Olson & Paul J. Maddon
Serial No.: 09/464,902
Filed : December 16, 1999
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-77. (Cancelled)

- 78. (Withdrawn) An anti-CCR5 antibody designated PA14 (ATCC Accession No. HB-12610) or other antibody which binds to the same epitope as PA14.--
- 79. (Withdrawn) A humanized form of the antibody of claim 78.--
- 80. (Withdrawn) The antibody of claim 79, wherein some, most or all of the amino acids outside the CDR regions have been replaced with amino acids from human immunoglobulin molecules but where some, most or all amino acids within one or more CDR regions are unchanged.--
- 81. (Withdrawn) An isolated nucleic acid molecule encoding the light chain of the monoclonal antibody of any one of claims 78-80.
- 82. (Withdrawn) The nucleic acid molecule of claim 81, wherein the nucleic acid molecule is an RNA molecule, a DNA molecule or cDNA molecule.
- 83. (Withdrawn) An isolated nucleic acid molecule encoding the heavy chain of the monoclonal antibody of any one of claims 78-80.

Applicants: William C. Olson & Paul J. Maddon
Serial No.: 09/464,902
Filed : December 16, 1999
Page 3

- 84. (Withdrawn) The nucleic acid molecule of claim 83, wherein the nucleic acid molecule is an RNA molecule, a DNA molecule or cDNA molecule.
- 85. (Withdrawn) One or more isolated nucleic acid molecules encoding the Fab portion of the monoclonal antibody of any one of claims 78-80.
- 86. (Withdrawn) The nucleic acid molecule of claim 85, wherein the nucleic acid molecule is an RNA molecule, DNA molecule or cDNA molecule.
- 87. (Previously Presented) An isolated nucleic acid molecule encoding one or more CDR regions of an anti-chemokine receptor 5 (CCR5) monoclonal antibody designated PA 14 (ATCC Accession No. HB-12610), monoclonal antibody designated PA 8 (ATCC Accession No. HB-12605), monoclonal antibody designated PA 9 (ATCC Accession No. HB-12606), monoclonal antibody designated PA 10 (ATCC Accession No. HB-12607), monoclonal antibody designated PA 11 (ATCC Accession No. HB-12608), or monoclonal antibody designated PA 12 (ATCC Accession No. HB-12609).--
- 88. (Previously Presented) The nucleic acid molecule of claim 87, wherein the nucleic acid molecule is an RNA molecule, DNA molecule or cDNA molecule.
- 89. (Withdrawn) One or more isolated nucleic acid molecules encoding the variable domain of the monoclonal antibody of any one of claims 78-80.

Applicants: William C. Olson & Paul J. Maddon
Serial No.: 09/464,902
Filed : December 16, 1999
Page 4

- 90. (Withdrawn) The nucleic acid molecule of claim 89, wherein the nucleic acid molecule is an RNA molecule, DNA molecule or cDNA molecule.
- 91. (Previously Presented) The nucleic acid molecule according to claim 87, wherein the CDR regions bind to an epitope of CCR5, said epitope comprises amino acid residues in (1) an N-terminus of CCR5, (2) amino acid residues in one of three extracellular loop regions of CCR5, or (3) a combination thereof.--
- 92. (Previously Presented) The nucleic acid molecule according to claim 87, wherein the CDR region is comprised within an Fab portion of the antibody.--
- 93. (Previously Presented) The nucleic acid molecule according to claim 87, wherein the CDR region is comprised within a variable domain of the antibody.--
- 94. (Previously Presented) The nucleic acid molecule according to claim 87, wherein the CDR region is comprised within an F(ab')₂ portion of the antibody.--
- 95. (Previously Presented) The nucleic acid molecule according to claim 87, wherein the nucleic acid coding the CDR region is comprised in a hybridoma selected from the group of hybridomas consisting of PA 14 (ATCC Accession No. HB-12610), PA 8 (ATCC Accession No. HB-12605), PA 9 (ATCC Accession No. HB-12606), PA 10 (ATCC Accession No. HB-12607), PA 11 (ATCC Accession No. HB-12608), and PA 12 (ATCC

Applicants: William C. Olson & Paul J. Maddon
Serial No.: 09/464,902
Filed : December 16, 1999
Page 5

Accession No. HB-12609).--

- 96. (Withdrawn) A nucleic acid molecule encoding an anti-CCR5 monoclonal antibody or portion thereof, said portion comprising one or more CDR regions, wherein the anti-CCR5 monoclonal antibody is selected from the group consisting of monoclonal antibody designated PA 14 (ATCC Accession No. HB-12610), monoclonal antibody designated PA 8 (ATCC Accession No. HB-12605), monoclonal antibody designated PA 9 (ATCC Accession No. HB-12606), monoclonal antibody designated PA 10 (ATCC Accession No. HB-12607), monoclonal antibody designated PA 11 (ATCC Accession No. HB-12608), and monoclonal antibody designated PA 12 (ATCC Accession No. HB-12609).--
- 97. (Withdrawn) The nucleic acid molecule according to claim 96, wherein the CDR regions bind to an epitope of CCR5, said epitope comprises amino acid residues in (1) an N-terminus of CCR5, (2) amino acid residues in one of three extracellular loop regions of CCR5, or (3) a combination thereof.--
- 98. (Currently Amended) The nucleic acid molecule according to claim [[95]] 96, wherein the portion is an Fab portion of the antibody.--
- 99. (Currently Amended) The nucleic acid molecule according to claim [[95]] 96, wherein the portion is a variable domain of the antibody.--
- 100. (Currently Amended) The nucleic acid molecule according to claim [[95]] 96, wherein the portion

Applicants: William C. Olson & Paul J. Maddon
Serial No.: 09/464,902
Filed : December 16, 1999
Page 6

is an F(ab')₂ of the antibody.--

--101. (Currently Amended) The nucleic acid molecule according to claim [[95]] 96, wherein the nucleic acid encoding the anti-CCR5 monoclonal antibody or portion thereof is comprised in a hybridoma selected from the group of hybridomas consisting of PA 14 (ATCC Accession No. HB-12610), PA 8 (ATCC Accession No. HB-12605), PA 9 (ATCC Accession No. HB-12606), PA 10 (ATCC Accession No. HB-12607), PA 11 (ATCC Accession No. HB-12608), and PA 12 (ATCC Accession No. HB-12609).---